Why Is ZYMEWORKS INC (ZYME) Stock Down Today?

Zymeworks (ZYME) shares fell 5.83% to $29.63, a move that occurred despite the company reporting third quarter earnings that exceeded consensus estimates. The primary driver of the decline appears to be a post-earnings sell-off following a strong run in the preceding weeks, as the stock had gained 10.0% over the last eight sessions prior to the drop.

What Happened

Zymeworks reported third quarter 2026 financial results, posting earnings per share of $2.28 against a consensus estimate of $2.19. The company also raised its full year 2026 sales guidance from a previous range of $278 million to $292 million to a new range of $337 million to $351 million, which compares to an estimated $302.672 million.

Following the report, several analysts adjusted their outlooks. Citi raised its price target to $44 from $39. TD Cowen maintained its Buy rating and raised its price target to $39. Truist Securities also maintained its Buy rating, raising its price target to $36. Additionally, HC Wainwright & Co. maintained its Buy rating and raised its price target to $56.

What The Data Shows

The stock opened at $31.30, representing a 0.5% gap down from the prior close of $31.46. The session high was $31.94 at 9:30 AM ET, while the session low reached $29.00 at 10:10 AM ET. Volume so far stands at 0.1 million shares, which is 0.1 times the three month daily average.

Fundamentals show a market cap of $2.2 billion with a P/E ratio of 56.6. Revenue has grown 97.8% on a trailing twelve month basis, and the net margin is 16.3%. The stock has a beta of 1.30 and a 52 week range of $16.57 to $31.97. Recent insider activity includes a sale by Adam Schayowitz, EVP and Head of R and D, on October 9, 2026. Over the last 90 days, there have been no insider buys and one sale totaling $358,000. The stock printed eight fresh 52 week lows on November 11, 2026.

What To Watch

Investors will monitor how the stock reacts to the raised full year guidance and the updated analyst price targets. The recent insider sale and the high valuation relative to earnings will likely remain focal points for near term trading activity.